CA2875749C - Composition pharmaceutique pour traiter la forme pulmonaire du mal de l'altitude causee par la rarefaction de l'oxygene et la diminution de la pression atmospherique - Google Patents

Composition pharmaceutique pour traiter la forme pulmonaire du mal de l'altitude causee par la rarefaction de l'oxygene et la diminution de la pression atmospherique Download PDF

Info

Publication number
CA2875749C
CA2875749C CA2875749A CA2875749A CA2875749C CA 2875749 C CA2875749 C CA 2875749C CA 2875749 A CA2875749 A CA 2875749A CA 2875749 A CA2875749 A CA 2875749A CA 2875749 C CA2875749 C CA 2875749C
Authority
CA
Canada
Prior art keywords
peptide
cyclized
seq
pharmaceutical composition
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2875749A
Other languages
English (en)
Other versions
CA2875749A1 (fr
Inventor
Bernhard Fischer
Rudolf Lucas
Hendrik Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apeptico Forschung und Entwicklung GmbH
Original Assignee
Apeptico Forschung und Entwicklung GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2875749(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Apeptico Forschung und Entwicklung GmbH filed Critical Apeptico Forschung und Entwicklung GmbH
Publication of CA2875749A1 publication Critical patent/CA2875749A1/fr
Application granted granted Critical
Publication of CA2875749C publication Critical patent/CA2875749C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un peptide comportant 7 à 20, et en particulier 7 à 17 acides aminés voisins, et contenant l'hexamère TX1EX2X3E, X1. Dans ladite formule, X2 et X3 peuvent chacun représenter un acide aminé naturel ou non naturel. Ce peptide ne présente aucune activité de liaison de récepteur de TNF, et est cyclisé, ce qui permet de l'utiliser pour traiter et éviter la forme pulmonaire du mal de l'altitude.
CA2875749A 2012-06-28 2013-06-19 Composition pharmaceutique pour traiter la forme pulmonaire du mal de l'altitude causee par la rarefaction de l'oxygene et la diminution de la pression atmospherique Active CA2875749C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12173983.3 2012-06-28
EP12173983.3A EP2679239A1 (fr) 2012-06-28 2012-06-28 Composition pharmaceutique pour le traitement de la forme pulmonaire du mal d'altitude provoqué par le manque d'oxygène et la pression atmosphérique réduite
PCT/EP2013/062777 WO2014001177A1 (fr) 2012-06-28 2013-06-19 Composition pharmaceutique pour traiter la forme pulmonaire du mal de l'altitude causée par la raréfaction de l'oxygène et la diminution de la pression atmosphérique

Publications (2)

Publication Number Publication Date
CA2875749A1 CA2875749A1 (fr) 2014-01-03
CA2875749C true CA2875749C (fr) 2019-02-26

Family

ID=48672620

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2875749A Active CA2875749C (fr) 2012-06-28 2013-06-19 Composition pharmaceutique pour traiter la forme pulmonaire du mal de l'altitude causee par la rarefaction de l'oxygene et la diminution de la pression atmospherique

Country Status (14)

Country Link
US (2) US9802985B2 (fr)
EP (2) EP2679239A1 (fr)
JP (1) JP6113277B2 (fr)
KR (1) KR102010793B1 (fr)
CN (1) CN104427993B (fr)
AP (1) AP2014008162A0 (fr)
AU (1) AU2013283563B2 (fr)
CA (1) CA2875749C (fr)
EA (1) EA030384B1 (fr)
ES (1) ES2602197T3 (fr)
IN (1) IN2015DN00585A (fr)
MX (1) MX354302B (fr)
PE (1) PE20150198A1 (fr)
WO (1) WO2014001177A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2939635A1 (fr) * 2014-03-04 2015-09-11 Apeptico Forschung Und Entwicklung Gmbh Attenuation d'une inflammation intrapulmonaire
ES2665180T3 (es) * 2014-03-18 2018-04-24 Apeptico Forschung Und Entwicklung Gmbh Medicamento de péptido en forma de polvo seco
EP3365275A4 (fr) 2015-08-25 2019-06-26 Bar-Ilan University Appareil à cellules électrochimiques asymétriques et ses procédés de fonctionnement
US11439869B2 (en) 2017-05-19 2022-09-13 Trudell Medical International Positive expiratory pressure device
USD903097S1 (en) 2018-05-18 2020-11-24 Trudell Medical International Mask
USD874064S1 (en) 2018-05-18 2020-01-28 Trudell Medical International Mask
USD893806S1 (en) 2018-11-09 2020-08-18 Trudell Medical Internationl Mask and shroud
WO2021087037A1 (fr) * 2019-10-29 2021-05-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide de ciblage spécifique du poumon (ltp), compositions et utilisations associées
IL294894A (en) 2020-05-08 2022-09-01 Apeptico Forschung & Entwicklung Gmbh A peptide for the prevention or treatment of covid-19
KR20250164550A (ko) 2024-05-16 2025-11-25 장태현 고산병 예방을 위한 입술용 화장료 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1228459B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore con svuotamento regolare e completo della capsula.
US5891679A (en) 1993-02-03 1999-04-06 N.V. Innogenetics S.A. TNF-alpha muteins and a process for preparing them
CZ302862B6 (cs) * 1998-08-14 2011-12-21 Lécivo na lécení otoku
JP5108515B2 (ja) * 2004-08-06 2012-12-26 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺サーファクタント及びｔｎｆ由来ペプチドを含有する組成物
EP2009023A1 (fr) 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Nouveaux peptides et leur utilisation pour le traitement de l'oedème
AT506150B1 (de) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
MX2011009251A (es) * 2009-03-04 2011-11-18 Mannkind Corp Sistema mejorado de suministro de farmaco en polvo seco.
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
AT510585B1 (de) 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase

Also Published As

Publication number Publication date
KR20150037815A (ko) 2015-04-08
KR102010793B1 (ko) 2019-08-14
US9802985B2 (en) 2017-10-31
EP2679239A1 (fr) 2014-01-01
CA2875749A1 (fr) 2014-01-03
EA030384B1 (ru) 2018-07-31
US20150225460A1 (en) 2015-08-13
WO2014001177A1 (fr) 2014-01-03
EP2866824A1 (fr) 2015-05-06
AP2014008162A0 (en) 2014-12-31
ES2602197T3 (es) 2017-02-20
CN104427993A (zh) 2015-03-18
CN104427993B (zh) 2017-03-08
AU2013283563A1 (en) 2015-01-15
IN2015DN00585A (fr) 2015-06-26
AU2013283563B2 (en) 2017-06-08
MX2014015048A (es) 2015-06-05
US20190211061A1 (en) 2019-07-11
EP2866824B1 (fr) 2016-08-10
JP6113277B2 (ja) 2017-04-12
MX354302B (es) 2018-02-23
JP2015526399A (ja) 2015-09-10
PE20150198A1 (es) 2015-02-19
EA201500061A1 (ru) 2015-06-30

Similar Documents

Publication Publication Date Title
AU2013283563B2 (en) Pharmaceutical composition for treatment of the pulmonary form of altitude sickness caused by lack of oxygen and reduced air pressure
US20230250164A1 (en) IL-18 Binding Protein (IL-18BP) In Inflammatory Diseases
CA1341060C (fr) Utilisation d'agonistes d'amyline dans le traitement du diabete sucre
US20140179614A1 (en) Metallothionein-Derived Peptide Fragments
US20180000888A1 (en) Vasopressin formulations for use in treatment of hypotension
CA2708134C (fr) Proteine cyclique exempte de cysteine
CA2785185C (fr) Composes organiques pour la regulation de canaux ioniques vectoriels
US20240325496A1 (en) Cxc chemokine agonists and antagonists in covid-19 disease and diagnostic assays
ANDO et al. Lack of effect of α-human atrial natriuretic polypeptide on volume reabsorption and p-aminohippuric acid secretion in the rabbit proximal straight tubule
US8372799B2 (en) Reverse protein

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180425

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20241219